Medical Treatment & Drug Development
Post-Doctoral Fellowships
Israel
Studying multi-drug resistance implications of the 'excludon', a novel antisense-based regulatory structure in bacteria
Getting the Better of Antibiotic Resistance
To add or modify information on this page, please contact us at the following address: community.research@axa.com

Ofir
COHEN
Institution
Weizmann Institute of Science
Country
Israel
Nationality
Israeli
Related articles
Chronic & Non-communicable Diseases
Medical Treatment & Drug Development
AXA Project
France
Pain Pediatric & Elderly AXA Research Lab (PEARL)
Cutaneous neuropathic pain is a highly debilitating chronic condition, characterized by persistent sensations of burning, tingling, or hypersensitivity. It disproportionately... Read more
Celine
GRECO
Hôpital Necker-Enfants Malades
Medical Treatment & Drug Development
Post-Doctoral Fellowship
Germany
Fighting bacterial infection by targeting the ability of pathogens to hijack the body's defense system
Towards developing a new generation of antibiotics that target bacterial ubiquitin ligases used to hijack the host cells Dr. Timurs... Read more

Timurs
MACULINS
Goethe University Frankfurt
Mental Health & Neurology
Medical Treatment & Drug Development
AXA Chair
Spain
Finding a cure to the irreversible damages caused by spinal cord injuries
Building a bridge to restore communication in the spinal cord Our brain communicates with the rest of our body through... Read more

Maurizio
PRATO